A randomized phase 1 study of the safety and immunogenicity of 2 novel pneumococcal conjugate vaccines in healthy Japanese adults in the United States

References

• World Health Organization. 23-valent pneumococcal polysaccharide vaccine. WHO position paper. Wkly Epidemiol Rec. 2008;83(42):373–84.
   PubMedGoogle Scholar
• Wald ER. Acute otitis media and acute bacterial sinusitis. Clin Infect Dis. 2011;52 Suppl 4(Suppl4):S277–283. doi:10.1093/cid/cir042.
   PubMedGoogle Scholar
• Collaborators GBDLRI. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018;18(11):1191–210. doi:10.1016/S1473-3099(18)30310-4.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Pneumococcal vaccines WHO position paper–2012. Wkly Epidemiol Rec. 2012;87(14):129–44.
   PubMedGoogle Scholar
• National Institute of Infectious Diseases and Tuberculosis and Infectious Diseases Control Division. Pneumococcal infections in 2017. Japan: Ministry of Health, Labour and Welfare of Japan; 2018.
   Google Scholar
• Said MA, Johnson HL, Nonyane BA, Deloria-Knoll M, O’Brien KL, AGEDD Adult Pneumococcal Burden Study Team, Andreo F, Beovic B, Blanco S, Boersma WG, et al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One. 2013;8(4):e60273. doi:10.1371/journal.pone.0060273.
   PubMed Web of Science ®Google Scholar
• McLaughlin JM, Jiang Q, Isturiz RE, Sings HL, Swerdlow DL, Gessner BD, Carrico RM, Peyrani P, Wiemken TL, Mattingly WA, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against hospitalization for community-acquired pneumonia in older US adults: a test-negative design. Clin Infect Dis. 2018;67(10):1498–506. doi:10.1093/cid/ciy312.
   PubMed Web of Science ®Google Scholar
• Geno KA, Gilbert GL, Song JY, Skovsted IC, Klugman KP, Jones C, Konradsen HB, Nahm MH. Pneumococcal capsules and their types: past, present, and future. Clin Microbiol Rev. 2015;28(3):871–99. doi:10.1128/CMR.00024-15.
   PubMed Web of Science ®Google Scholar
• Shiramoto M, Irie S, Juergens C, Yamaji M, Tamai S, Aizawa M, Belanger T, Gruber WC, Scott DA, Schmoele-Thoma B. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine when administered to healthy Japanese adults aged ≥50 years: an open-label trial. Hum Vaccin Immunother. 2014;10(7):1850–58. doi:10.4161/hv.28633.
   PubMed Web of Science ®Google Scholar
• Frenck RW Jr., Fiquet A, Gurtman A, van Cleeff M, Davis M, Rubino J, Smith W, Sundaraiyer V, Sidhu M, Emini EA, et al. Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older. Vaccine. 2016;34(30):3454–62. doi:10.1016/j.vaccine.2016.04.093.
   PubMed Web of Science ®Google Scholar
• Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AM, Sanders EA, Verheij TJ, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114–25. doi:10.1056/NEJMoa1408544.
   PubMed Web of Science ®Google Scholar
• Suga S, Chang B, Asada K, Akeda H, Nishi J, Okada K, Wakiguchi H, Maeda A, Oda M, Ishiwada N, et al. Nationwide population-based surveillance of invasive pneumococcal disease in Japanese children: effects of the seven-valent pneumococcal conjugate vaccine. Vaccine. 2015;33:6054–60. doi:10.1016/j.vaccine.2015.07.069.
   PubMed Web of Science ®Google Scholar
• Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, Petit S, Zansky SM, Harrison LH, Reingold A, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15(3):301–09. doi:10.1016/S1473-3099(14)71081-3.
   PubMed Web of Science ®Google Scholar
• Myint TT, Madhava H, Balmer P, Christopoulou D, Attal S, Menegas D, Sprenger R, Bonnet E. The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review. Adv Ther. 2013;30(2):127–51. doi:10.1007/s12325-013-0007-6.
   PubMed Web of Science ®Google Scholar
• Fukusumi M, Chang B, Tanabe Y, Oshima K, Maruyama T, Watanabe H, Kuronuma K, Kasahara K, Takeda H, Nishi J, et al. Invasive pneumococcal disease among adults in Japan, April 2013 to March 2015: disease characteristics and serotype distribution. BMC Infect Dis. 2017;17(1):2. doi:10.1186/s12879-016-2113-y.
   PubMedGoogle Scholar
• Hausdorff WP, Hanage WP. Interim results of an ecological experiment - conjugate vaccination against the pneumococcus and serotype replacement. Hum Vaccin Immunother. 2016;12(2):358–74. doi:10.1080/21645515.2015.1118593.
   PubMed Web of Science ®Google Scholar
• Metcalf BJ, Gertz RE Jr., Gladstone RA, Walker H, Sherwood LK, Jackson D, Li Z, Law C, Hawkins PA, Chochua S, et al. Strain features and distributions in pneumococci from children with invasive disease before and after 13-valent conjugate vaccine implementation in the USA. Clin Microbiol Infect. 2016;22(1):60.e69-60.e29. doi:10.1016/j.cmi.2015.08.027.
   Web of Science ®Google Scholar
• Tomczyk S, Lynfield R, Schaffner W, Reingold A, Miller L, Petit S, Holtzman C, Zansky SM, Thomas A, Baumbach J, et al. Prevention of antibiotic-nonsusceptible invasive pneumococcal disease with the 13-valent pneumococcal conjugate vaccine. Clin Infect Dis. 2016;62(9):1119–25. doi:10.1093/cid/ciw067.
   PubMed Web of Science ®Google Scholar
• Vadlamudi NK, Chen A, Marra F. Impact of 13-pneumococcal conjugate vaccine among adults: a systematic review and meta-analysis. Clin Infect Dis. 2018. doi:10.1093/cid/ciy872.
   Web of Science ®Google Scholar
• Wantuch PL, Avci FY. Invasive pneumococcal disease in relation to vaccine type serotypes. Hum Vaccin Immunother. 2019;15(4):874–75. doi:10.1080/21645515.2018.1564444.
   PubMed Web of Science ®Google Scholar
• Isturiz RE, Ramirez J, Self WH, Grijalva CG, Counselman FL, Volturo G, Ostrosky-Zeichner L, Peyrani P, Wunderink RG, Sherwin R, et al. Pneumococcal epidemiology among US adults hospitalized for community-acquired pneumonia. Vaccine. 2019;37(25):3352–61. doi:10.1016/j.vaccine.2019.04.087.
   PubMed Web of Science ®Google Scholar
• Balsells E, Guillot L, Nair H, Kyaw MH. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a systematic review and meta-analysis. PLoS One. 2017;12(5):e0177113. doi:10.1371/journal.pone.0177113.
   PubMed Web of Science ®Google Scholar
• Cui YA, Patel H, O’Neil WM, Li S, Saddier P. Pneumococcal serotype distribution: a snapshot of recent data in pediatric and adult populations around the world. Hum Vaccin Immunother. 2017;13(6):1–13. doi:10.1080/21645515.2016.1277300.
   Web of Science ®Google Scholar
• Yahiaoui RY, Bootsma HJ, Den Heijer CDJ, Pluister GN, John Paget W, Spreeuwenberg P, Trzcinski K, Stobberingh EE. Distribution of serotypes and patterns of antimicrobial resistance among commensal Streptococcus pneumoniae in nine European countries. BMC Infect Dis. 2018;18(1):440. doi:10.1186/s12879-018-3341-0.
   PubMedGoogle Scholar
• Pneumovax® 23 (pneumococcal vaccine polyvalent). Full prescribing information. Whitehouse Station (NJ): Merck & Co., Inc.; 2015.
   Google Scholar
• Thompson A, Lamberth E, Severs J, Scully I, Tarabar S, Ginis J, Jansen KU, Gruber WC, Scott DA, Watson W. Phase1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults. Vaccine. 2019;37(42):6201–07. doi:10.1016/j.vaccine.2019.08.048.
   PubMed Web of Science ®Google Scholar
• Hurley D, Griffin C, Young M, Scott DA, Pride MW, Scully IL, Ginis J, Severs J, Jansen KU, Gruber WC, et al. Safety, tolerability, and immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in adults 60 to 64 years of age. Clin Infect Dis. 2020. doi:10.1093/cid/ciaa1045.
   Google Scholar
• Clutterbuck EA, Lazarus R, Yu LM, Bowman J, Bateman EA, Diggle L, Angus B, Peto TE, Beverley PC, Mant D, et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis. 2012;205(9):1408–16. doi:10.1093/infdis/jis212.
   PubMed Web of Science ®Google Scholar
• Sings HL. Pneumococcal conjugate vaccine use in adults - addressing an unmet medical need for non-bacteremic pneumococcal pneumonia. Vaccine. 2017;35:5406–17. doi:10.1016/j.vaccine.2017.05.075.
   PubMed Web of Science ®Google Scholar
• Yildirim I, Shea KM, Pelton SI. Pneumococcal disease in the era of pneumococcal conjugate vaccine. Infect Dis Clin North Am. 2015;29(4):679–97. doi:10.1016/j.idc.2015.07.009.
   PubMed Web of Science ®Google Scholar
• Daniels CC, Rogers PD, Shelton CM. A review of pneumococcal vaccines: current polysaccharide vaccine recommendations and future protein antigens. J Pediatr Pharmacol Ther. 2016;21(1):27–35. doi:10.5863/1551-6776-21.1.27.
   PubMedGoogle Scholar
• Schuchat A. Pneumococcal prevention gets older and wiser. JAMA Intern Med. 2015;175(12):1897–98. doi:10.1001/jamainternmed.2015.6133.
   PubMed Web of Science ®Google Scholar
• Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013;1:CD000422. doi:10.1002/14651858.CD000422.pub3.
   PubMed Web of Science ®Google Scholar
• Pfizer Inc. Pfizer initiates phase 3 program for 20-valent pneumococcal conjugate vaccine for the prevention of invasive disease and pneumonia in adults aged 18 years and older. Business Wire. [accessed 2020 July 5]. https://www.businesswire.com/news/home/20181214005069/en/.
   Google Scholar